No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial

J.P. Ferreira*, N. Girerd, H.P. Brunner-La Rocca, P. Pellicori, J.G. Cleland, P. Rossignol, F. Zannad

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Original languageEnglish
Pages (from-to)814-817
Number of pages4
JournalArchives of Cardiovascular Diseases
Volume114
Issue number12
DOIs
Publication statusPublished - 1 Dec 2021

Keywords

  • SARS-CoV-2
  • COVID-19
  • Spironolactone
  • RECEPTOR
  • ACE2
  • RISK

Cite this